Compare Neurocrine Biosciences Inc (NBIX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Standard Lithium Ltd — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: Neurocrine Biosciences Inc is far larger — about 33.2× Standard Lithium Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| NBIX | SLI | |
|---|---|---|
Market Cap | $17.40B | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $180.55 | $5.65 |
52-Week Low | $123.10 | $2.15 |
Enterprise Value | $16.49B | $383.09M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
